Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial
Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial. // ESMO Open. – URL: https://www.sciencedirect.com/science/article/pii/S2059702926025822?dgcid=rss_sd_all
Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial. ESMO Open. https://www.sciencedirect.com/science/article/pii/S2059702926025822?dgcid=rss_sd_all
“Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial.” ESMO Open.
@article{article98952,
title = {Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial},
journal = {ESMO Open},
url = {https://www.sciencedirect.com/science/article/pii/S2059702926025822?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment